SEC-sourced researchBeta

NKTR

NEKTAR THERAPEUTICS

US markets

Data passport

CIK: 0000906709
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Oct 1, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 9:09 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

NKTR · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2024	98,427,000.0000	Mar 13, 2026
December 2025	55,232,000.0000	Mar 13, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	55,232,000.0000	-164,076,000.0000	-208,511,000.0000	280,406,000.0000	190,574,000.0000	Mar 13, 2026
December 2024	98,427,000.0000	-118,961,000.0000	-175,709,000.0000	303,850,000.0000	243,113,000.0000	Mar 13, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$55.23M	December 2025	Mar 13, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$98.43M	December 2024	Mar 13, 2026	10-K
Net incomeNetIncomeLoss	-$164.08M	December 2025	Mar 13, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$208.51M	December 2025	Mar 13, 2026	10-K
Total assetsAssets	$280.41M	December 2025	Mar 13, 2026	10-K
Total liabilitiesLiabilities	$190.57M	December 2025	Mar 13, 2026	10-K

New filings

Explore methodology ↗